TAK-659 hydrochloride

CAS No. 1952251-28-3

TAK-659 hydrochloride( Mivavotinib | TAK 659 | TAK659 )

Catalog No. M13056 CAS No. 1952251-28-3

TAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 68 In Stock
10MG 102 In Stock
25MG 205 In Stock
50MG 312 In Stock
100MG 484 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    TAK-659 hydrochloride
  • Note
    Research use only, not for human use.
  • Brief Description
    TAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM.
  • Description
    TAK-659 hydrochloride (Mivavotinib, TAK659) is a potent, selective and orally available SYK inhibitor with IC50 of 3.2 nM; displays 36, 42 and 23-fold selectivity over JAK3, ZAP70 and VEGFR2, respectively; also potently inhibits FLT-3; inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines, demonstrates potent tumor growth inhibition in the FLT3-dependent MV4-11 xenograft models.Blood Cancer Phase 2 Clinical(In Vitro):TAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells.(In Vivo):TAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow.
  • In Vitro
    TAK-659 hydrochloride inhibits cellular proliferation in SYK-dependent DLBCL and FLT3-dependent AML cell lines.TAK-659 hydrochloride (5 μM; 1-24 hours) induces Casp3 activation in the LMP2A/MYC cells which was readily apparent at 4 h and reached maximum levels at 8 h of treatment.TAK-659 hydrochloride (0.01-10 μM; 1 hour) stimulates expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 increased in Ramos cells. Apoptosis Analysis Cell Line:LMP2A/MYC cells Concentration:5 μM Incubation Time:1 hour, 2 hours, 4 hours, 8 hours, 24 hours Result:Induced apoptosis in LMP2A/MYC lymphoma cells.Western Blot Analysis Cell Line: Ramos cells Concentration: 0.01 μM,0.1 μM,1 μM,10 μM Incubation Time:1 hour Result:Enhanced expression of phospho-Syk at Tyr525 and Tyr352 and phospho-ERK1/2 in stimulated Ramos cells.
  • In Vivo
    TAK-659 hydrochloride (100 mg/kg/day; p.o.; daily, for 10 days) treatment totally abrogates splenomegaly and tumor development in LMP2A/MYC mice in both pretumor and tumor cell transfer experiments.TAK-659 hydrochloride treatment kills tumor cells, but not host cells within the spleen and tumors.TAK-659 hydrochloride treatment abrogates metastasis of tumor cells into bone marrow. Animal Model:LMP2A/MYC double transgenic mice Dosage:100 mg/kg/day Administration:Oral gavage; for 10 daysResult:Inhibited LMP2A-induced tumor cell survival in vivo.
  • Synonyms
    Mivavotinib | TAK 659 | TAK659
  • Pathway
    Angiogenesis
  • Target
    Syk
  • Recptor
    FLT3|JAK3|Syk|VEGFR2|ZAP70
  • Research Area
    Cancer
  • Indication
    Blood cancer

Chemical Information

  • CAS Number
    1952251-28-3
  • Formula Weight
    380.852
  • Molecular Formula
    C17H22ClFN6O
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO: <1 mg/mL; Ethanol: <1 mg/mL; Water: 4 mg/mL (10.5 mM), warmed ( < 1 mg/ml refers to the product slightly soluble or insoluble )
  • SMILES
    CN1C=C(C=N1)C2=NC(=C(C3=C2C(=O)NC3)F)NC4CCCCC4N.Cl
  • Chemical Name
    6-(((1R,2S)-2-aminocyclohexyl)amino)-7-fluoro-4-(1-methyl-1H-pyrazol-4-yl)-1,2-dihydro-3H-pyrrolo[3,4-c]pyridin-3-one hydrochloride

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lam B, et al. Bioorg Med Chem Lett. 2016 Dec 15;26(24):5947-5950. 2. Purroy N, et al. Oncotarget. 2017 Jan 3;8(1):742-756.
molnova catalog
related products
  • R406

    R406 is a potent Syk inhibitor with IC50 of 41 nM, strongly inhibits Syk but not Lyn, 5-fold less potent to Flt3. Phase 1.

  • Mitapivat

    Mitapivat, also known as PKM2 activator 1020 is a PKM2 activator (pyruvate kinase activator) for the treatment of pyruvate kinase deficiency.

  • TC-S 7003

    TC-S 7003 (Lck Inhibitor) is an orally active, selective and potent lymphocyte kinase (Lck) inhibitor with anti-inflammatory activity, inhibition of Lck, Lyn, Src, and Syk kinases, and inhibition of T-cell proliferation, and may be useful in the study of arthritis.